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Metabolism and Toxicity of Styrene
by Kenneth C. Leibman*
The absorption, blood levels, distribution, excretion, and biotransformation of styrene
in man and experimental animals are briefly reviewed. The acute toxicity of styrene
appears to be unrelated to its biotransformation. Reports of organ toxicity upon chronic
exposure to styrene are rare; however, since the chief intermediate in styrene metabo-
lism is an epoxide, hepatotoxicity due to covalent binding at the site of formation
appears to be a possibility.
Styrene (phenylethylene, vinylbenzene) is an
important intermediate in chemical synthesis
and monomer for plastics manufacture. It is a
colorless, refractive, oily liquid of density d20 =
4
0.909. Its melting and boiling points are -33
and 146°C, respectively. It is sparingly soluble
in water, but soluble in most organic solvents.
Its vapor has a characteristic, penetrating odor,
the perception of which diminishes as exposure
is continued (1).
Styrene may be absorbed into the blood-
stream by all routes: on peroral administration
or inhalation, by percutaneous absorption, or
after subcutaneous or intraperitoneal adminis-
tration. The most common routes of absorp-
tion in industrial exposure are pulmonary and
percutaneous. The ACGIH recommended thres-
hold limit value (TLV) is 100 ppm (420 mg/m3
of air).
Blood levels of styrene that have been re-
ported (1) in man after exposure for varying
periods to air containing different concentra-
tions of styrene are shown in Table 1. Expo-
sures were continuous for the indicated times,
except for that of 410-min duration, which was
scheduled to simulate exposure for a full
working day to the TLV concentration; sub-
jects were exposed for 3.5 hr, given a 30-min
lunch period, and again exposed for 3.5 hr,
and blood samples were drawn 10 min before
the end of the second period.
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As would be expected from its high lipid
solubility, the rate of percutaneous absorption
of styrene is high (2). The absorption rate of
liquid styrene through the skin of the hand is
9-15 mg/cm2-hr. That for aqueous solutions
(66-269 mg/l.) is 40-180 Ug/cm2-hr; the rate
was found to be linear with concentration. A
few minutes' exposure of the hands to liquid
styrene, or exposure to a saturated aqueous
solution for about 1 hr, may result in the ab-
sorption of as much styrene as does breathing
air containing 50 mg/m3 for 8 hr.
Concentrations of styrene found in rodent
organs after exposure of the animals to the LC50
(3) are shown in Table 2. There appears to be
a fairly uniform distribution of styrene among
the aqueous compartments of the body, as would
be expected from the high lipid solubility of
the compound; the latter property also leads
to extensive sequestration of styrene in the fat.
After subcutaneous injection of [13-14C]
styrene in oil (4), the blood was essentially
cleared of radioactivity within 24 hr (Table 3).
By that time, about 85%o of the radioactivity
had been excreted. Most of the radioactivity was
Table 1. Human blood concentrations of styrene.
Exposure, Time, Blood concentration,
ppm min mg/i.
51 55 0.2-0.7
99 410 0.9-1.4
117 55 1.7
117 115 2.7
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,8-carbon was oxidized to CO2. There is a con-
siderable excretion of unchanged styrene in
the expired air as well. Thus, in the experi-
ment referred to above in which a day's ex-
posure to the TLV concentration was simulated,
the concentration of styrene in the expired air
was about 4.5 ppm shortly after cessation of
exposure and was still 0.3 ppm 6 hr later (1).
The metabolites of styrene found in the
urine of rats, rabbits, and man are shown in
Table 4. A major metabolite in rodents is
hippuric acid; in man, however, the level of
urinary hippuric acid after exposure to styrene
is generally in the normal range of excretion
of this compound, which is quite variable
(1,12,13). Mandelic and phenylglyoxylic acids
are prominent metabolites; these are the major
metabolites that have been demonstrated in
man, and they have been proposed as indices
of exposure to styrene (12,13). Although the
ratio of mandelic to phenylglyoxylic acid ex-
creted after experimental human exposure to
styrene was reported by Bardodej and Bardo-
dejova (7) to be 8.5, the concentration ratio
in urine samples taken at 3 P.M. from factory
workers exposed to 10-13 ppm during the day
was found by Ohtsuji and Ikeda to be about 2
(12). The glucuronide excreted by rats was
shown to be that of phenylethylene glycol (8).
The half-lives of urinary excretion of man-
delic and phenylglyoxylic acids in man after
exposure to 50-200 ppm of styrene for 160
min were 7.8 and 8.5 hr, respectively (13). In
contrast, the half-life of pulmonary excretion
of unchanged styrene after the exposures shown
in Table 1 varied from 1 to 5 hr (1).
The production of mandelic, phenylglyoxylic,
and hippuric acids and of glucuronide conju-
gates has been shown to be increased in rats
Table 3. Disposition of radioactivity after subcutaneous
injection of[,B-1.4C] styrene in rats.
1 hr 6 hr 24 hr
Radioactivity in organs, % of
dose
Site of injection 57.2 28.0 2.1
Blood 1.0 0.8 0.02
Liver 4.6 1.0 0.1
Kidneys 1.8 0.5 0.01
Othera 2.7 0.9 0.2
Radioactivity in excreta,
cumulative % of dose
Urine 4.0 37.2 71.0
Feces 0.0 0.4 2.6
Expired C02 0.0 6.0 11.8
a Pancreas, lungs, stomach, intestine, heart, spleen,
adrenals, bone, brain, thymus.
Table 4. Urinary metabolites of styrene.
Rat, Rabbit, Man, %
Metabolite % of % of of retained
dose dose dose
Mandelic acid 98 32b 850
Phenylglyoxylic acid ill 100
Hippuric acid 10" 40d +
Glucuronide 8& 6d
Sulfur compounds
"Neutral" sulfur + ++
Hydroxymercap-
turic acid 9g 5b
4-Vinylphenol 0. lh
1-Phenylethanol +h
2-Phenylethanol Trace
a Dose, 4.4 mmole/kg IP; 10-hr collection (5).
b Dose, 1.4 mmole/kg PO; 24-hr collection (6).
e Inhalation exposure to 22 ppm for 8 hr; collection period
unspecified (7).
d Dose, 5 mmole/kg PO; 24-hr collection (8).
e Repeated doses PO or by inhalation (9).
f Inhalation exposure to 800 ppm for 4 hr; 24-hr collec-
tion (10).
* Dose, 2.0 mmole/kg PO; 24-hr collection (6).
h Dose, 1.0 mmole/kg PO; 48-hr collection (11).
rodent organs after
Organ Rat, Mouse,
mg/100 ga mg/100 gb
Brain 25.0 18.0
Liver 20.0
Kidney 14.7
Spleen 19.1
Perirenal fat 133
a LCso: 11.8 mg/l., 4-hr exposure.
b LC05: 21.0 mg/l., 2-hr exposure.
after pretreatment with phenobarbital (5,14),
and to be inhibited by coadministration of
SKF 525-A, an inhibitor of microsomal drug-
metabolizing enzymes: (5). Coadministration
of toluene, which is known to be oxidized by
the hepatic microsomal enzyme system, also
reduced the formation of the three acids (14).
It would thus appear that a primary step in
styrene metabolism is catalyzed by liver micro-
somal enzymes.
The most probable pathways of mammalian
styrene metabolism are shown in Figure 1. The
first steps of the chief pathway have been
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Table 2. Styrene concentrations in
exposure to LC50.
116HO-C6H4-CH=CH2
4-Vinylphenol
T
C6H5-CH=CH2
Styrene
I C6H5-CH-CH,
OH
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C6H5-CH2CH20H
2-Phenylethanol
C6H5-CH-CH NHCOCHs
OH S-CH2CH2COOH
Hydroxyphenethyl
Mercapturic Acid
C6H5-CH-CH \/
Styrene
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2 C6H5-CH-CH2
OH OH
Phenylethylene
Glycol
I
C02 + C6H5-COOH
Benzoic Acid
I,
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C6H5-CH-COOH
OH
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0
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FIGURE 1. Pathways of biotransformation of styrene. Underlined metabolites are those that are excreted
in urine (or in expired air in the case of C02).
demonstrated by Leibman and Ortiz (15-17)
to occur in vitro in rat and rabbit liver micro-
somal preparations: The major product detected
after incubation of styrene with liver micro-
somes in the presence of an NADPH-generating
system was phenylethylene glycol (15). After
short incubation periods, the production of
small amounts of styrene oxide could be demon-
strated (16); epoxide levels rapidly fell there-
after, as the hydration of the oxide, mediated
by microsomal epoxide hydrase (17), proceeded.
However, the incorporation of substantial radio-
activity from [,8-14C]styrene into a pool of un-
labeled styrene oxide was demonstrated (16),
The conversion of both, styrene and styrene
oxide to hydroxyphenethylmercapturic acid
has been shown.to occur in vivo in rats and
rabbits by James and White (6). The first step
in this process, conjugation of the epoxide with
glutathione, has been demonstrated in vitro in
rat liver cytosol (18) and in a purified enzyme
preparation (19).
Glucuronide and mandelic, phenylglyoxylic,
and hippuric acids have all been found to be
excreted after administration of styrene, sty-
rene oxide, or phenylethylene glycol to rats
and rabbits (5,6,8), which demonstrates that
the epoxide-diol pathway is intermediate in
the production of the major metabolites of
styrene. Hippuric acid is excreted after ad-
ministration of mandelic, but not of phenyl-
glyoxylic acid, while mandelic acid gives rise
to phenylglyoxylic acid, but the reverse appar-
ently does not occur (5). Since more hippuric
acid is produced in vivo from phenylethylene
glycol.than from mandelic acid (5), it would
appear that two pathways exist for formation
of this compound.
Minor metabolic pathways of styrene in rats
include ring hydroxylation and formation of 1-
and 2-phenylethanol (8). Whether the produc-
tion of the latter metabolites involves styrene
oxide is not known.
The urinary metabolites of styrene all have
a lower order of toxicity than does styrene
itself, and therefore do not contribute to its
acute toxicity. The LD50 of styrene in rats is
about 2.5 g/kg after intraperitoneal injection
(5) and about 5 g/kg after oral administration
(20). The acute toxicity of styrene oxide is
about four times that of styrene (5).
The acute toxicity of styrene appears to be
unrelated to its biotransformation, but is simi-
lar to that of other hydrocarbons. The most
common toxic actions after exposure to styrene
vapors or liquid are irritation of the skin,
eyes, and respiratory tract, and depression of
the central nervous system. At or below the
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117TLV, there are no subjective symptoms or
objective signs in man on short exposure. With
continued exposure, mild eye and throat irri-
tation develops, and there is slight impairment
of coordination and balance. At higher air con-
centrations, nasal, eye, throat, and skin irri-
tation becomes more pronounced. There is a
decrease in coordination, balance, and manual
dexterity. Nausea, headache, fatigue, and a
feeling of drunkenness have been reported.
As with other hydrocarbons, chemical pneu-
monitis is a great hazard if aspiration occurs
after ingestion of styrene.
Organ toxicity has been reported for sty-
rene, but appears to be rare. In one experiment
(9), rats, guinea pigs, rabbits, and monkeys
were exposed to 1300 ppm of styrene for 7-8
hr/day, 5 days/week for 6 months. The only
deaths due to styrene occurred among the
guinea pigs, 10%So of which developed acute
lung inflammation, edema and hemorrhage. All
surviving animals had normal weight gains,
and at the end of the experimental period, no
abnormal microscopic tissue changes or altera-
tions in the blood picture could be found. After
oral administration of 667 mg/kg-day, 5 days/
week for 6 months, however, depression of
growth was noted, together with a moderate
increase in liver weight and a slight increase
in kidney weight (20).
Epoxide intermediates have been implicated
in hepatotoxicity (21) and carcinogenicity (22).
Styrene oxide has been found to have little
or no carcinogenic potency after long-term
skin-painting in mice (23,24), but was reported
to cause malignant lymphomas in mice after
administration by an unspecified route (25).
Covalent binding of styrene oxide at the site
of formation in liver, with resultant hepato-
toxicity, analogous to that postulated for
bromobenzene epoxide (26), appears a distinct
possibility, especially under conditions where
glutathione has been depleted or the activity
of epoxide hydrase has been reduced. Clinical
hepatotoxicity has apparently been reported
very rarely after styrene exposure. Two reports
have appeared in the Russian literature in
which liver enlargement and decrease in liver
function were found in workers exposed to
styrene (27,28), but it is likely that these
workers were exposed to a number of other
chemicals as well as to styrene. It would appear,
however, that an investigation of possible
covalent binding of styrene metabolites in liver
would be a worthwhile project.
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